Table 4 Priorities stratified by site
From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
| Variable | Aggregate | China | Japan | South Korea | Taiwan | Chi-squared p-value |
|---|---|---|---|---|---|---|
| Coef ( SE ) | Coef ( SE ) | Coef ( SE ) | Coef ( SE ) | Coef ( SE ) | ||
| Monitoring at-risk populations | 13.75*** | 9.17** | 16.67*** | 17.08*** | 12.08*** | 0.20 |
| (1.5) | (3.1) | (2.7) | (3.3) | (2.5) | ||
| Risk Assessment | 5.42*** | 5.83* | 0.83 | 7.08* | 7.92** | 0.18 |
| (1.3) | (2.4) | (2.4) | (2.9) | (2.4) | ||
| Access to treatments | 5.21*** | 10.83*** | 5.83* | 1.25 | 2.92 | 0.11 |
| (1.4) | (3.0) | (2.4) | (2.7) | (3.2) | ||
| National guidelines | 8.96*** | 14.17*** | 10.00*** | 7.92** | 3.75 | 0.02* |
| (1.4) | (2.8) | (3.3) | (2.7) | (2.0) | ||
| Research infrastructure | 3.96** | 4.17 | 6.67* | 3.75 | 1.25 | 0.63 |
| (1.4) | (2.5) | (2.8) | (2.5) | (3) | ||
| Centers of excellence | 6.86*** | 5.83* | 10.00*** | 6.25* | 5.42* | 0.60 |
| (1.5) | (3.9) | (2.5) | (1.9) | (3.1) | ||
| Multidisciplinary management | 8.33*** | 7.50** | 11.67*** | 6.25* | 7.92** | 0.44 |
| (1.4) | (2.4) | (2.1) | (3.4) | (2.7) | ||
| Clinician education | 11.04*** | 7.50** | 10.83*** | 15.42*** | 10.42*** | 0.15 |
| (1.3) | (2.3) | (3.2) | (2.5) | (2.6) | ||
| Public awareness | 8.13*** | 3.33 | 6.67* | 11.25*** | 11.25*** | 0.11 |
| (1.4) | (2.7) | (2.8) | (2.7) | (2.6) | ||
| Transplantation infrastructure | 0.42 | −8.33 | 5.83 | −0.42 | 4.58 | 0.01** |
| (1.5) | (3.6) | (2.4) | (2.7) | (2.7) | ||
| Measuring Social Burden | 5.21*** | 2.50 | 2.50 | 2.92 | 12.92*** | 0.04* |
| (1.4) | (2.5) | (2.7) | (2.4) | (3.1) |